Efficacy and Safety of a New Formulation of Pancrelipase (Ultrase MT20) in the Treatment of Malabsorption in Exocrine Pancreatic Insufficiency in Cystic Fibrosis

Table 2

Dietary intake and absorption in the mITT population (𝑛=24).

	Treatment		Treatment
	Pancrelipase	Placebo	Difference∗
Fat intake (g/day)	116.9±21.9 (77–168)	119.8±29.8 (69–219)
Protein intake (g/day)	119.5±39.6 (40–216)	120.0±36.3 (40–188)
CFA (%)	88.6±5.0 (77–97)	53.9±25.5 (14–97)	34.7±25.0 (−7–75)
CNA (%)	84.0±7.4 (62–95)	58.3±20.6 (30–96)	25.7±17.7 (−9–52)

All values expressed as mean ± 1 standard deviation (range).
∗Mean treatment difference determined from within-patient differences.
CFA: coefficient of fat absorption; CAN: coefficient of nitrogen absorption; mITT: modified Intent-To-Treat (patients completing both treatment periods).